휴미라(Humira) 약제 시장 : 시장 규모, 점유율, 동향 및 성장 분석(2026-2034년)

The global humira drug market size is expected to reach USD 15.99 Billion in 2034 from USD 10.10 Billion in 2025, growing at a CAGR of 5.24 during 2026-2034.This market continues to hold a significant position in the pharmaceutical industry due to the widespread use of Humira in treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis. The growing prevalence of chronic inflammatory conditions and increasing awareness regarding biologic therapies are significantly driving market demand. Healthcare providers and patients are increasingly adopting advanced biologic medications because of their effectiveness in managing complex immune-related disorders. Rising healthcare expenditure and improved access to specialty treatments are also contributing to market growth globally.

The increasing demand for targeted therapies and advancements in biotechnology are major factors supporting market expansion. Pharmaceutical companies are investing heavily in research and development to improve biologic drug formulations and treatment outcomes. The growing geriatric population and rising incidence of autoimmune diseases are also creating sustained demand for effective therapeutic solutions. In addition, the expansion of healthcare infrastructure and improved insurance coverage for biologic medications are encouraging greater adoption of advanced autoimmune disease treatments across developed and emerging regions.

Future prospects for the Humira drug market remain favorable despite increasing competition from biosimilar products. Companies are expected to focus on next-generation biologics, combination therapies, and personalized medicine approaches to strengthen market positioning. Advancements in biotechnology and drug delivery systems are likely to improve treatment efficiency and patient compliance. Emerging markets are also anticipated to provide substantial growth opportunities as healthcare accessibility improves and awareness regarding chronic disease management continues to increase worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Branded
• Biosimilar

By Application

• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Crohn-(TM)s Disease (CD)
• Ulcerative Colitis (UC)
• Ankylosing Spondylitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Alvotech, Amgen Inc., Boehringer Ingelheim Pharmaceuticals Inc., CELLTRION INC., Coherus BioSciences Inc., Fresenius Kabi AG, FUJIFILM KYOWA KIRIN BIOLOGICS Co. Ltd., Pfizer Inc., Samsung Bioepis, Sandoz Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMIRA DRUG MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Biosimilar Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMIRA DRUG MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Rheumatoid Arthritis (RA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Psoriatic Arthritis (PsA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Crohn-(TM)s Disease (CD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Ulcerative Colitis (UC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Ankylosing Spondylitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMIRA DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMIRA DRUG MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMIRA DRUG INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Alvotech
  • 9.2.2 Amgen Inc
  • 9.2.3 Boehringer Ingelheim Pharmaceuticals Inc
  • 9.2.4 CELLTRION INC
  • 9.2.5 Coherus BioSciences Inc
  • 9.2.6 Fresenius Kabi AG
  • 9.2.7 FUJIFILM KYOWA KIRIN BIOLOGICS Co. Ltd
  • 9.2.8 Pfizer Inc
  • 9.2.9 Samsung Bioepis
  • 9.2.10 Sandoz Inc